Evidence map›Paper›PMID 40362175›Full record

ArticleInternational journal of molecular sciences2025

A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of

Swatika Butey, Morgan L Brown, Janet R Julson, Raoud Marayati, Venkatram R Atigadda, Maryam G Shaikh, Nazia Nazam, Colin H Quinn, Sorina Shirley, Laura L Stafman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Swatika ButeyDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-1334-7073
Morgan L BrownDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-2729-8244
Janet R JulsonDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-8213-443X
Raoud MarayatiDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-2848-3927
Venkatram R AtigaddaDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-0085-0403
Maryam G ShaikhDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Nazia NazamDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Colin H QuinnDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-7853-3948
Sorina ShirleyDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Laura L StafmanDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-3952-1017
Elizabeth A BeierleDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-4613-0527

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Suzanne Elizabeth Lapi · 1985 to 2026
$165.9M
Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancerR01CA276683 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Venkatram Reddy Atigadda · 2023 to 2026
$2.4M
Destiny StrongER Foundation N/AKaul Pediatric Research Foundation N/ANCI/NIH 5RO1CA276683NCI/NIH 5T32-GM008361NCI/NIH T32-CA229102NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA276683UAB Comprehensive Flow Cytometry Core P30 AR048311, P20 AI027767UAB Genomics Core S10OD032422-1
6 · The paper itself

Abstract

Hepatoblastoma (HB) is the most common pediatric primary liver tumor. About 20% of affected children have pulmonary metastasis at presentation. Survival rates for these children are dismal, not exceeding 25%. To study this subset of patients, we sequenced a metastatic HB cell line, HLM_2, and identified downregulation of the Liver X Receptor (LXR)/Retinoid X Receptor (RXR) pathway. LXR/RXRs function as transcriptional regulators that influence genes implicated in HB development, including the Wnt/β-catenin signaling pathway. We assessed the effects of a novel LXR/RXR agonist, UAB116, on metastatic HB, hypothesizing that this compound would affect genes governing the Wnt/β-catenin pathway, decreasing the metastatic phenotype of HLM_2 metastatic HB cells. We evaluated its effects on viability, proliferation, stemness, clonogenicity, and motility, and performed RNA sequencing to study differential gene regulation. Treatment with UAB116 for 72 h decreased HLM_2 proliferation, stemness, clonogenicity, and invasion. RNA sequencing identified an eight-fold increase in

Indexed as

DNA-Binding ProteinsHepatoblastomaLiver NeoplasmsTranscription FactorsWnt Signaling Pathwaybeta CateninCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansLiver X ReceptorsNeoplasm MetastasisPhenotypeUp-Regulationbeta CateninDNA-Binding ProteinsLiver X ReceptorsTranscription Factorshepatoblastomaliver X receptor (LXR)retinoid X receptor (RXR)tripartite motif containing 29 (TRIM 29)Wnt/β-catenin

Identifiers

PMID40362175
PMCPMC12072001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.